Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Home
Research units
Researchers
Projects & Grants
Research Output
Facilities & Equipment
Honors & Awards
Activities
Search by expertise, name or affiliation
A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 tp 75 Years Old with Newly Diagnosed FLT3-ITD
Qasrawi, Ayman
(PI)
Hildebrandt, Gerhard
(Former PI)
Markey Cancer Center / Cancer Research Priority Initiative
Overview
Grants and Contracts Details
Status
Finished
Effective start/end date
9/21/16
→
10/6/23
Funding
Daiichi Sankyo Incorporated:
$147,866.00
View all
View less